Statement: the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression.
Primary_evidence: INTERVENTION 1:    Pemetrexed   600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression